Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

NCT06561048 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Peripheral T-Cell Lymphoma, Not Otherwise Specified
Angioimmunoblastic T-cell Lymphoma
Follicular T-Cell Lymphoma
Nodal Peripheral T-Cell Lymphoma With TFH Phenotype
Systemic Anaplastic Large Cell Lymphoma
Lymphoma, T-Cell, Peripheral
Lymphoma, T-Cell

Interventions

DRUG: Soquelitinib
DRUG: Belinostat
DRUG: Pralatrexate

Sponsor

Corvus Pharmaceuticals, Inc.